Palivizumab

Therapeutic indications

Palivizumab is indicated for:

Prevention of respiratory syncytial virus (RSV) infection

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Palivizumab is indicated for the prevention of serious lower respiratory tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:

  • Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
  • Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
  • Children less than 2 years of age and with haemodynamically significant congenital heart disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: SYNAGIS Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈